Cargando…

miRNA-based biomarkers, therapies, and resistance in Cancer

MicroRNAs (miRNAs), small non-coding RNAs (ncRNAs) of about 22 nucleotides in size, play important roles in gene regulation, and their dysregulation is implicated in human diseases including cancer. A variety of miRNAs could take roles in the cancer progression, participate in the process of tumor i...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Boxue, Zhao, Zhenyu, Cai, Qidong, Zhang, Yuqian, Zhang, Pengfei, Shi, Shuai, Xie, Hui, Peng, Xiong, Yin, Wei, Tao, Yongguang, Wang, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415433/
https://www.ncbi.nlm.nih.gov/pubmed/32792861
http://dx.doi.org/10.7150/ijbs.47203
_version_ 1783569174142910464
author He, Boxue
Zhao, Zhenyu
Cai, Qidong
Zhang, Yuqian
Zhang, Pengfei
Shi, Shuai
Xie, Hui
Peng, Xiong
Yin, Wei
Tao, Yongguang
Wang, Xiang
author_facet He, Boxue
Zhao, Zhenyu
Cai, Qidong
Zhang, Yuqian
Zhang, Pengfei
Shi, Shuai
Xie, Hui
Peng, Xiong
Yin, Wei
Tao, Yongguang
Wang, Xiang
author_sort He, Boxue
collection PubMed
description MicroRNAs (miRNAs), small non-coding RNAs (ncRNAs) of about 22 nucleotides in size, play important roles in gene regulation, and their dysregulation is implicated in human diseases including cancer. A variety of miRNAs could take roles in the cancer progression, participate in the process of tumor immune, and function with miRNA sponges. During the last two decades, the connection between miRNAs and various cancers has been widely researched. Based on evidence about miRNA, numerous potential cancer biomarkers for the diagnosis and prognosis have been put forward, providing a new perspective on cancer screening. Besides, there are several miRNA-based therapies among different cancers being conducted, advanced treatments such as the combination of synergistic strategies and the use of complementary miRNAs provide significant clinical benefits to cancer patients potentially. Furthermore, it is demonstrated that many miRNAs are engaged in the resistance of cancer therapies with their complex underlying regulatory mechanisms, whose comprehensive cognition can help clinicians and improve patient prognosis. With the belief that studies about miRNAs in human cancer would have great clinical implications, we attempt to summarize the current situation and potential development prospects in this review.
format Online
Article
Text
id pubmed-7415433
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-74154332020-08-12 miRNA-based biomarkers, therapies, and resistance in Cancer He, Boxue Zhao, Zhenyu Cai, Qidong Zhang, Yuqian Zhang, Pengfei Shi, Shuai Xie, Hui Peng, Xiong Yin, Wei Tao, Yongguang Wang, Xiang Int J Biol Sci Review MicroRNAs (miRNAs), small non-coding RNAs (ncRNAs) of about 22 nucleotides in size, play important roles in gene regulation, and their dysregulation is implicated in human diseases including cancer. A variety of miRNAs could take roles in the cancer progression, participate in the process of tumor immune, and function with miRNA sponges. During the last two decades, the connection between miRNAs and various cancers has been widely researched. Based on evidence about miRNA, numerous potential cancer biomarkers for the diagnosis and prognosis have been put forward, providing a new perspective on cancer screening. Besides, there are several miRNA-based therapies among different cancers being conducted, advanced treatments such as the combination of synergistic strategies and the use of complementary miRNAs provide significant clinical benefits to cancer patients potentially. Furthermore, it is demonstrated that many miRNAs are engaged in the resistance of cancer therapies with their complex underlying regulatory mechanisms, whose comprehensive cognition can help clinicians and improve patient prognosis. With the belief that studies about miRNAs in human cancer would have great clinical implications, we attempt to summarize the current situation and potential development prospects in this review. Ivyspring International Publisher 2020-07-19 /pmc/articles/PMC7415433/ /pubmed/32792861 http://dx.doi.org/10.7150/ijbs.47203 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
He, Boxue
Zhao, Zhenyu
Cai, Qidong
Zhang, Yuqian
Zhang, Pengfei
Shi, Shuai
Xie, Hui
Peng, Xiong
Yin, Wei
Tao, Yongguang
Wang, Xiang
miRNA-based biomarkers, therapies, and resistance in Cancer
title miRNA-based biomarkers, therapies, and resistance in Cancer
title_full miRNA-based biomarkers, therapies, and resistance in Cancer
title_fullStr miRNA-based biomarkers, therapies, and resistance in Cancer
title_full_unstemmed miRNA-based biomarkers, therapies, and resistance in Cancer
title_short miRNA-based biomarkers, therapies, and resistance in Cancer
title_sort mirna-based biomarkers, therapies, and resistance in cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415433/
https://www.ncbi.nlm.nih.gov/pubmed/32792861
http://dx.doi.org/10.7150/ijbs.47203
work_keys_str_mv AT heboxue mirnabasedbiomarkerstherapiesandresistanceincancer
AT zhaozhenyu mirnabasedbiomarkerstherapiesandresistanceincancer
AT caiqidong mirnabasedbiomarkerstherapiesandresistanceincancer
AT zhangyuqian mirnabasedbiomarkerstherapiesandresistanceincancer
AT zhangpengfei mirnabasedbiomarkerstherapiesandresistanceincancer
AT shishuai mirnabasedbiomarkerstherapiesandresistanceincancer
AT xiehui mirnabasedbiomarkerstherapiesandresistanceincancer
AT pengxiong mirnabasedbiomarkerstherapiesandresistanceincancer
AT yinwei mirnabasedbiomarkerstherapiesandresistanceincancer
AT taoyongguang mirnabasedbiomarkerstherapiesandresistanceincancer
AT wangxiang mirnabasedbiomarkerstherapiesandresistanceincancer